Company intelligence / Profile preview
Beijing Imunopharm
Beijing, Beijing, Chinaysbiopharm.com ↗
- Ownership
- Private
- Employees
- ~800
- Development stage
- Other
01
Overview
YS Biopharma, formerly known as Yisheng Biopharma and often referred to in early records as Beijing Imunopharm, is a global biopharmaceutical company dedicated to discovering, developing, and commercializing innovative vaccines and therapeutic biologics. The company utilizes its proprietary PIKA adjuvant technology platform to enhance immune responses, focusing on infectious diseases and oncology. Its lead commercial product, YSJA, is a conventional human rabies vaccine widely used in China. The company's pipeline includes next-generation PIKA-adjuvanted rabies vaccines and COVID-19 vaccines, as well as immunotherapeutic candidates for chronic hepatitis B and various solid tumors.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineBiologicRecombinant proteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ruyi HealthTavotek Biotherapeutics
Beyond the preview
Go deeper on Beijing Imunopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Imunopharm.